ImpediMed partners with Vanderbilt to test device

Company News

by Jessica Ellerm

 
ImpediMed Limited (ASX:IPD) has announced it will partner with Vanderbilt University for a series of clinical trials involving patients and clinicians.
 
The trial will test the hardware and software behind ImpediMed’s latest bioimpedance spectroscopy technology platform.
 
Researchers will observe the technology in use in both clinical and at-home settings.
 
Research will be undertaken at the Vanderbilt University School of Nursing, which is part of the independent and privately supported Vanderbilt University.
 
ImpediMed Limited reported a net loss of $11.22 million at 31 December 2015.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.